Ogden Angela, Rida Padmashree C G, Reid Michelle D, Aneja Ritu
Department of Biology, Georgia State University, Atlanta, GA 30303, USA.
Department of Pathology, Emory University Hospital, Atlanta, GA 30322, USA.
Drug Discov Today. 2014 Jul;19(7):824-9. doi: 10.1016/j.drudis.2013.10.022. Epub 2013 Nov 4.
Microtubule-targeting agents (MTAs) profoundly affect interphase cells, such as by disrupting axonal transport, transcription, translation, mitochondrial permeability, immune cell function, directional migration and centrosome clustering. This finding is antithetical to the conventionally held notion that MTAs act on mitosis to trigger arrest-mediated apoptotic cell death. Furthermore, the paucity of mitotic cells in patient tumors and lack of correlation of MTA efficacy with tumor proliferation rate provide strong impetus to re-examine the mechanistic basis of action of MTAs, with an eye toward interphase activities. Whereas targeted antimitotics have unequivocally failed their promise across clinical studies, MTAs constitute a mainstay of chemotherapy. This paradox necessitates the conclusion that MTAs exert mitosis-independent effects, spurring a dramatic paradigm shift in our understanding of the mode of action of MTAs.
微管靶向剂(MTAs)对间期细胞有深远影响,例如通过破坏轴突运输、转录、翻译、线粒体通透性、免疫细胞功能、定向迁移和中心体聚集。这一发现与传统观念相悖,传统观念认为MTAs作用于有丝分裂以触发停滞介导的凋亡性细胞死亡。此外,患者肿瘤中有丝分裂细胞的稀缺以及MTA疗效与肿瘤增殖率缺乏相关性,为重新审视MTAs的作用机制基础提供了强大动力,着眼于间期活动。虽然靶向抗有丝分裂药物在临床研究中明确未能实现其承诺,但MTAs构成了化疗的主要支柱。这种矛盾使得必须得出结论,即MTAs发挥不依赖有丝分裂的作用,促使我们对MTAs作用模式的理解发生巨大的范式转变。